Crossmark

Long-lasting responses after discontinuation of nivolumab treatment for reasons other than tumor progression in patients with previously treated, advanced non-small cell lung cancer

Crossref DOI link: https://doi.org/10.1186/s40880-019-0423-3

Published Online: 2019-11-21

Published Print: 2019-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Kimura, Hideharu

Araya, Tomoyuki

Yoneda, Taro

Shirasaki, Hiroki

Kurokawa, Koji

Sakai, Tamami

Koba, Hayato

Tambo, Yuichi

Nishikawa, Shingo

Sone, Takashi

Kasahara, Kazuo
License Information

Text and Data Mining valid from 2019-11-21
More Information

Article History

Received: 22 June 2019

Accepted: 13 November 2019

First Online: 21 November 2019

Ethics approval and consent to participate

: Approval for the study was obtained from the Institutional Review Board of Kanazawa University (approved #2423-2) and conformed to the Declaration of Helsinki.

: Not applicable.

: KK: Grant support from Ono pharmaceutical and Bristol-Myers Squibb. The other authors declare that they have no competing interests.

Document is current

Any future updates will be listed below